Try our beta test site

Evaluating Liraglutide in Alzheimer's Disease (ELAD)

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2016 by Imperial College London
King's College Hospital NHS Trust
University of Oxford
University of Southampton
Avon and Wiltshire Mental Health Partnership NHS Trust
Information provided by (Responsible Party):
Imperial College London Identifier:
First received: April 24, 2013
Last updated: September 30, 2016
Last verified: September 2016

This is a 12-month, multicentre randomised double-blind placebo-controlled Phase IIb study in patients with mild Alzheimer's dementia (AD). The investigators aim to recruit patients with mild Alzheimer's dementia as defined by the National Institute of Neurological and Communicative Disorders and Stroke - Alzheimer's Disease and Related Disorder Association (NINCDS-ADRDA) Criteria for Probable Alzheimer's Dementia or meeting Dubois criteria for early AD, with Mini Mental State Evaluation score of at least 22 out of a maximum of 30 and a CDR Global score of 0.5 or 1.

Patients will be randomised on a 1:1 ratio to receive liraglutide or identical matching placebo.

Condition Intervention Phase
Alzheimer's Disease
Drug: Liraglutide
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Evaluating the Effects of the Novel GLP-1 Analogue, Liraglutide, in Patients With Mild Alzheimer's Disease (ELAD Study)

Resource links provided by NLM:

Further study details as provided by Imperial College London:

Primary Outcome Measures:
  • The change in cerebral glucose metabolic rate [ Time Frame: 12 months ]
    The change in cerebral glucose metabolic rate from baseline to follow up (12 months) in the treatment group compared with the placebo group.

Secondary Outcome Measures:
  • The change in z-scores for the ADAS Exec, MRI changes, microglial activation, and CSF markers [ Time Frame: 12 months ]
  • The incidence and severity of treatment emergent adverse events [ Time Frame: 12 months ]
    The incidence and severity of treatment emergent adverse events or clinically important changes in safety assessments over 12 months.

Estimated Enrollment: 206
Study Start Date: January 2014
Estimated Study Completion Date: March 2019
Estimated Primary Completion Date: March 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Liraglutide
Daily administration of 1.8 mg liraglutide by subcutaneous injection
Drug: Liraglutide
Daily subcutaneous injection
Other Name: Victoza
Placebo Comparator: Placebo
Daily administration of matched placebo by subcutaneous injection
Drug: Placebo
Daily subcutaneous injection


Ages Eligible for Study:   50 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Capable of giving and capacity to give informed consent. (Advanced directive will be taken from all patients regarding whether they would like to continue in the study in case they lose their capacity during the study. Carers will be actively involved in the consent process at the beginning of the study)
  2. A carer who can act as a reliable study partner
  3. Diagnosis of Probable Alzheimer's disease according to Dubois criteria (Dubois, Feldman et al. 2007) or National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria
  4. Age from 50 to 85 years, inclusive
  5. Mini-Mental State Examination (MMSE) score of ≥22
  6. Rosen Modified Hachinski Ischemic score ≤4
  7. On stable medication for 3 months; on or off cholinesterase inhibitors
  8. Fluency in English and evidence of adequate premorbid intellectual functioning
  9. Likely to be able to participate in all scheduled evaluations and complete all required tests

Exclusion Criteria:

  1. Diabetes
  2. Any contraindications to the use of liraglutide as per the Summary of Product Characteristics. (hepatic impairment, renal impairment with CKD stage 3 and above, inflammatory bowel disease)
  3. Significant neurological disease other than AD that may affect cognition
  4. MRI/CT showing unambiguous aetiological evidence of cerebrovascular disease with regard to their dementia
  5. Currently taking or having taken memantine on the 30 days prior to screening
  6. Current presence of a clinically significant major psychiatric disorder (e.g., Major Depressive Disorder) according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)
  7. Current clinically significant systemic illness that is likely to result in deterioration of the patient's condition or affect the patient's safety during the study
  8. History of seizures, excluding febrile seizures in childhood
  9. Treatment with immunosuppressive medications (e.g. systemic corticosteroids) within the last 90 days (topical and nasal corticosteroids and inhaled corticosteroids for asthma are permitted) or chemotherapeutic agents for malignancy within the last 3 years
  10. Myocardial infarction within the last 1 year
  11. History of cancer within the last 5 years
  12. Other clinically significant abnormality on physical, neurological or laboratory examination that could compromise the study or be detrimental to the patient
  13. History of alcohol or drug dependence or abuse within the last 2 years
  14. Current use of anticonvulsant, anti-Parkinson's, anticoagulant (excluding the use of aspirin 325 mg/day or less) or narcotic medications
  15. Use of experimental medications for AD or any other investigational medication or device within 60 days. Patients who have been involved in a monoclonal antibody study are excluded unless it is known that they were receiving placebo in that trial
  16. Women of childbearing potential. Women who could become pregnant will be required to use adequate contraception throughout the trial
  17. Patients with a personal or family history of medullary thyroid carcinoma (MTC) and patients with multiple endocrine neoplasia type 2 (MEN2)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01843075

Contact: Paul Edison, PhD FRCPI +44 (0) 2033133275
Contact: Mazna Anjum, MSc

United Kingdom
Imperial College, Hammersmith Hospital Recruiting
London, United Kingdom, W12 0NN
Contact: Mazna Anjum, MSc   
Principal Investigator: Paul Edison, PhD FRCP(I)         
Sponsors and Collaborators
Imperial College London
King's College Hospital NHS Trust
University of Oxford
University of Southampton
Avon and Wiltshire Mental Health Partnership NHS Trust
Principal Investigator: Paul Edison, PhD FRCPI Imperial College London
  More Information

Responsible Party: Imperial College London Identifier: NCT01843075     History of Changes
Other Study ID Numbers: U1111-1131-9252
Study First Received: April 24, 2013
Last Updated: September 30, 2016

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Hypoglycemic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists processed this record on March 24, 2017